Patients With Polyneuropathy More Often Receive Opioids

Share this content:
Patients With Polyneuropathy More Often Receive Opioids
Patients With Polyneuropathy More Often Receive Opioids

TUESDAY, May 23, 2017 (HealthDay News) -- Polyneuropathy is associated with increased likelihood of receiving long-term opioids, although long-term opioids do not improve functional status markers, according to a study published online May 22 in JAMA Neurology.

E. Matthew Hoffman, D.O., Ph.D., from the Mayo Clinic in Rochester, Minn., and colleagues conducted a retrospective population-based cohort study of prescriptions given to patients with polyneuropathy and controls in ambulatory practice (2,892 and 14,435 patients, respectively). The authors examined long-term opioid therapy, defined by one or multiple consecutive opioid prescriptions resulting in 90 days or more of opioid use.

The researchers found that patients with polyneuropathy received long-term opioids more often than controls (18.8 versus 5.4 percent). After adjustment for medical comorbidity, patients with polyneuropathy who were receiving long-term opioids had multiple functional status markers that were modestly poorer, including increased reliance on gait aids (adjusted odds ratio, 1.9); there was no improvement in functional status markers with long-term use of opioids. Among patients with polyneuropathy receiving long-term opioids, adverse outcomes were more common, including depression, opioid dependence, and opioid overdose (adjusted hazard ratios, 1.53, 2.85, and 5.12, respectively).

"Polyneuropathy increased the likelihood of long-term opioid therapy," the authors write. "However, long-term opioid therapy did not improve functional status but rather was associated with a higher risk of subsequent opioid dependency and overdose."

Abstract/Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »